Abstracts Topics

Track A: Special Populations Safety

1. Newborn and pediatric patients
2. Women's Medicine and Maternal Health
3. Older Patients
4. Oncology Patients and immunotherapy
5. Key populations, PrEP and hormone therapy

Track ​B: Patient Engagement and Patient Organizations

1. Reporting by patients, caregivers and families
2. Patient organizations and advocacy
3. Education for patients
4. Human factors and strategies to increase reporting

Track C: Risk Management, Benefit-Risk and Communication

1. Benefit-risk assessment
2. Risk management plans and risk minimisation methods
3. Effectiveness of risk minimisation measures
4. Periodic safety reports (PSUR/PBRER)
5. Risk communication and digital misinformation

Track D: Drug-Related Problems

1. Self-medication, self-prescription and off-label use
2. Opioid misuse and abuse
3. Falsified and substandard medicines
4. Antimicrobial resistance    

Track E: Medication Errors and Patient Safety

1. Medication errors risk mitigation 
2. Human factors and ergonomics approach
3. Policies, regulation and coordinated actions
4. Hospital and community pharmacovigilance

Track F: Digital Transformation and AI in Pharmacovigilance

1. AI applications and responsible use
2. Generative AI and intelligent agents
3. Automation of case processing
4. Digital tools, telemedicine, wearables and apps
5. Standardisation, terminologies and interoperability (WHODrug, MedDRA)

Track G: Evidence Generation, Pharmacoepidemiology and Real-World Evidence

1. Real world evidence and big data
2. Pharmacoepidemiology
3. Drug utilisation studies
4. Databases and real-world data sources
5. Post-authorisation studies and active surveillance

Track H: Signal Detection and Management  

1. Signal detection and signal lifecycle
2. Disproportionality analysis and data mining
3. Signal detection in small databases
4. Causality assessment
5. Serious and unexpected adverse reactions: clinical characterisation

Track I: Regulatory Science, PV Systems and Cross-Border Cooperation

1. Harmonization and regulatory convergence
2. Reliance and worksharing
3. PV policies, transparency and governance
4. Regulatory affairs and product decisions
5. Inspections and good pharmacovigilance practices
6. PV system strengthening and outsourcing    

Track J: Education, Training and Professional Development

1. Education and qualification in PV
2. Training, certification and postgraduate programmes
3. Students involvement
4. Interdisciplinary and multidisciplinary work

Track K: Vaccines and Public Health

1. Vaccine safety and AEFI
2. Signal detection in vaccines
3. Public trust and communication in immunisation
4. Other public health problems and conditions

Track L: Medical Devices and Technovigilance

1. Medical devices risk mitigation
2. Combined drug-medical device safety
3. Policies, regulation and coordinated actions
4. Medical device case studies       

Track M: Wider PV Horizons

1. Advanced therapy medicinal products
2. Pharmacogenomics and personalised medicine
3. Biologicals, biosimilars and generics
4. Orphan medicines and rare diseases
5. New therapeutic groups: GLP-1 agonists and obesity
6. Herbal and traditional medicines and selfcare
7. Cosmetovigilance, biovigilance, eco-pharmacovigilance and veterinary products

Track N: Regional Advances in Pharmacovigilance    Transversal

1. ISoP Chapters advances
2. Local and national experiences
3. Latin American cooperation and integration

Track O: Miscellaneous Transversal

1. Miscellaneous